Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Vidac Pharma.

    Client Virtual Booth

    VIDAC PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Vidac Pharma
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Dr. Max Herzberg, 20-22 Wenlock Road, London N1 7GU
    Telephone
    Telephone
    +972 544257381
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vidacpharma.com/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vidac-pharma/
    Twitter
    Twitter
    https://twitter.com/VidacPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma

    Details:

    VDA-1102 (tuvatexib) is a novel Hexokinase 2 modulator small molecule drug which is under phase 2 clinical development for the treatment of mycosis fungoides, a form of cutaneous t-cell lymphoma.


    Lead Product(s): Tuvatexib

    Therapeutic Area: Oncology Product Name: VDA-1102

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 12, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vidac Pharma Presents High Efficacy in Multiple Solid Tumor Models for its Next-Generation Cancer Drug Candidate and Synergy with Standard-of-Care Treat...

    Details:

    VDA-1275 is a potent small molecule new chemical entity (NCE) with novel mechanism of action that selectively modulates VDAC/HK2 interaction. It is being developed for the treatment of solid tumors.


    Lead Product(s): VDA-1275,Sorafenib,Cisplatin

    Therapeutic Area: Oncology Product Name: VDA-1275

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 19, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vidac Pharma Reports Positive Interim Phase 2a Data in Orphan Disease Cutaneous T-cell lymphoma (CTCL) with Lead Asset VDA-1102

    Details:

    VDA-1102 (tuvatexib) is a topical VDAC/HK2 modulator drug, which is being evaluated in phase 2 clinical trials for the treatment of Mycosis Fungoides.


    Lead Product(s): Tuvatexib

    Therapeutic Area: Oncology Product Name: VDA-1102

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 29, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vidac Pharma to Conduct Phase 2b Study for Actinic Keratosis Therapeutic Candidate VDA-1102 with CentroDerm

    Details:

    VDA-1102 (tuvatexib) is a novel Hexokinase 2 modulator small molecule drug which is under phase 2 clinical development for the treatment of actinic keratosis.


    Lead Product(s): Tuvatexib

    Therapeutic Area: Dermatology Product Name: VDA-1102

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 19, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vidac Pharma Reports in Vitro Results Showing VDA-1275 Compatible with Classical Chemotherapy

    Details:

    VDA-1275 is a VDAC/HK2 interaction Modulator, small molecule drug, orally administered, which is currently being investigated for the treatment of solid tumor.


    Lead Product(s): VDA-1275

    Therapeutic Area: Oncology Product Name: VDA-1275

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 29, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search